期刊文献+

钠—葡萄糖协同转运蛋白2(SGLT2)抑制剂:2型糖尿病治疗新靶点 被引量:4

Sodium glucose co-transporter 2(SGLT2)inhibitors:A novel focus of type 2 diabetes mellitus treatment
原文传递
导出
摘要 近年来,钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂作为一种研发中独具潜力的新兴糖尿病口服药已成为关注热点。SGLT2是一种低亲和力的葡萄糖转运蛋白,其特异性表达于肾脏近端小管,并在肾脏对葡萄糖的重吸收作用中扮演着重要角色。因而,特异性抑制SGLT2蛋白能够减少近端小管对葡萄糖的重吸收,促进尿葡萄糖排泄,降低糖尿病患者的血糖水平,并具有较低的低血糖风险和减轻体重等一系列潜在优势。尽管这类药物目前仍在试验中,但其治疗T2DM的效果被寄予厚望,未来有可能成为服用口服降糖药或注射胰岛素患者的辅助用药。目前部分研发中的前沿药物的临床Ⅲ期试验结果将得到的风险受益比率,将最终决定此类药物在未来糖尿病治疗中的地位。 Among the novel classes of anti-diabetic oral agents, the sodium glucose co-transporter 2 (SGLT2) inhibitors have been the subject of particular attention. SGLT2 is a low-affinity transport system that is specifically expressed in proximal renal tubule of the kidney and plays a significant role in renal glucose reabsorption. SLGT2 inhibitors block the receptor in the proximal renal tubule in the kidney, thereby prompting glucose urinary excretion. This results not only in lowering glucose levels in the plasma, but also in aiding weight loss without inducing hypoglycemia. Although this group of medicine is still under investigation, their efficacy in the treatment of type 2 diabetes mellitus is very promising, SGLT2 inhibitors would be also expected to be beneficial in combination with insulin or other OHAs. Results of ongoing phase Ⅲ clinical trials are awaited and will determine whether the risk-benefit ratio will allow approval of this new class of agent for the management of type 2 diabetes mellitus.
作者 李原 王尧
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2011年第11期873-876,共4页 Chinese Journal of Diabetes
关键词 糖尿病 2型 钠-葡萄糖协同转运蛋白2 高血糖 Diabetes mellitus, type 2 Sodium-coupled glucose co-transporter 2 (SGLT2) Hyperglycemia
  • 相关文献

参考文献20

  • 1Haffner SJ, Cassells H. Hyperglycemia as a cardiovascular risk factor. Am J Med, 2003, 115.- $6-Sll.
  • 2Nathan DM, Burse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: A consensus alghoritm for the initiation and adjustment of therapy. A consensus state-ment l'or the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2006, 4% 1711-1721.
  • 3Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med, 2008, 358: 2630-2633.
  • 4Neumiller J J, White JR, Campbell RK. Sodium-glucose co- transport inhibitors:progress and therapeutic potential in type 2 diabetes mellitus. Drugs, 2010,70 : 377-385.
  • 5Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med, 2007, 261~32-43.
  • 6Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr, 2003, 89: 3-9.
  • 7Zhou L, Cryan EV, D~Andrea MR, et at. Human cardiomyo- cytes express high level of. Na/glucose eotransporter 1 (SC-LT1). J Cell Biochem, 2003, 90.. 339-346.
  • 8Lee YJ, Lee YJ, Han HJ. Regulatory mechanisms of a glucose cotransporters in renal proximal tubulecells. Kidney Int Sup- pl, 2007, 106: $27-$35.
  • 9Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SOLT-2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes, 2008, 57: 1723-1729.
  • 10List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with Dapagliflozin in type 2 diabetes mellitus. Diabe- tes Care, 2009, 32.. 650-657.

同被引文献50

  • 1曹卫华,隋萍,孙金红,侯纯荣,刘晓红,王晓玲.健康教育对提高Ⅱ型糖尿病患者遵医行为的效果评价[J].中国健康教育,2005,21(9):697-700. 被引量:20
  • 2王宇真,吕风民.2型糖尿病患者的合理治疗[J].中国医药,2009,4(z1):76-77.
  • 3ACCORD Study Group; ACCORD Eye Study Group,Chew EY,et al. Effects of medical therapies on retinopathy progression in type 2 diabetes [ J]. N Engl J Med ,2010,363 (3) :233-244.
  • 4Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle- aged men [ J]. JAMA,2002,288 (21) :2709-2716.
  • 5Kadota A, Hozawa A, Okamura T, et al. Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity: NIPPON DATA90, 1990-2000 [ J ]. Diabetes Care ,2007,30 ( 6 ) : 1533-1538.
  • 6Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial [ J]. Diabetes Care ,2007,30 (6) :1374-1383.
  • 7Praet SF, van Loon LJ. Exercise therapy in type 2 diabetes [J]. Acta Diabetol,2009,46 (4) :263-278.
  • 8Hordern MD, Coombes JS, Cooney LM, et ai. Effects of exercise intervention on myocardial function in type 2 diabetes [ J ]. Heart, 2009,95 ( 16 ) : 1343-1349.
  • 9Chien HH, Chang CT, Chu NF, et al. Effect of Glybufide-Metformin Combination Tablet in Patients with Type 2 Diabetes [J]. J Chin Med Assoc, 2007,70( 11 ) : 473-480.
  • 10Michael N. Cook, PHD1, Cynthia J, etal. Comment on Hortg etal. Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease [J]. Diabetes Care, 2005,28 (5) :995-1000.

引证文献4

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部